Global Alpha 1 Antitrypsin Deficiency Treatment Market 2018 by Manufacturers, Regions, Type and Application, Forecast to 2023
- SKU ID : GIR-GIR1807020049 13049835
- |
- Publishing Date: 24-Oct-2018
- |
- Region: Global
- |
- No. of pages: 150
Severe deficiency of alpha-1 antitrypsin (AAT) can cause early-onset emphysema and several liver diseases, including cirrhosis, neonatal hepatitis and hepatocellular carcinoma.
Scope of the Report:
This report focuses on the Alpha 1 Antitrypsin Deficiency Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The discovery of the structure and function of the AAT protein and the subsequent isolation and purification thereof have made possible alternative therapies aimed at preventing the progression of related pulmonary diseases (so-called "additional therapies"). The isolation of this gene and the advancement of gene therapy have further increased the possibility of specific treatment. Most specific treatments for AAT deficiency aim to increase plasma AAT levels (and thus elevated AAT concentrations in the interstitial lung) above the protection threshold. Other experimental therapeutic approaches attempt to interfere with the production of abnormal AAT proteins or to inhibit the polymerization of abnormal AAT proteins and to promote the secretion of AAT from hepatocytes. For patients with end-stage lung disease or liver disease, organ transplantation is another treatment option.
Currently, the most direct and effective way to increase AAT levels in plasma and interstitial lung is by intravenous infusion of pooled alpha-1 antitrypsin (pAAT).
The worldwide market for Alpha 1 Antitrypsin Deficiency Treatment is expected to grow at a CAGR of roughly 9.0% over the next five years, will reach 1980 million US$ in 2023, from 1190 million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Shire
LFB Biomedicaments
Abeona Therapeutics
Biogen
Applied Genetic Technologies
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Curaxys
ProMetic Life Sciences
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Augmentation Therapy
Bronchodilators
Corticosteroids
Oxygen Therapy
Market Segment by Applications, can be divided into
Hospitals
Specialty Clinics
Pharmacies
There are 15 Chapters to deeply display the global Alpha 1 Antitrypsin Deficiency Treatment market.
Chapter 1, to describe Alpha 1 Antitrypsin Deficiency Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Alpha 1 Antitrypsin Deficiency Treatment, with sales, revenue, and price of Alpha 1 Antitrypsin Deficiency Treatment, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Alpha 1 Antitrypsin Deficiency Treatment, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Alpha 1 Antitrypsin Deficiency Treatment market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Alpha 1 Antitrypsin Deficiency Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Scope of the Report:
This report focuses on the Alpha 1 Antitrypsin Deficiency Treatment in global market, especially in North America, Europe and Asia-Pacific, South America, Middle East and Africa. This report categorizes the market based on manufacturers, regions, type and application.
The discovery of the structure and function of the AAT protein and the subsequent isolation and purification thereof have made possible alternative therapies aimed at preventing the progression of related pulmonary diseases (so-called "additional therapies"). The isolation of this gene and the advancement of gene therapy have further increased the possibility of specific treatment. Most specific treatments for AAT deficiency aim to increase plasma AAT levels (and thus elevated AAT concentrations in the interstitial lung) above the protection threshold. Other experimental therapeutic approaches attempt to interfere with the production of abnormal AAT proteins or to inhibit the polymerization of abnormal AAT proteins and to promote the secretion of AAT from hepatocytes. For patients with end-stage lung disease or liver disease, organ transplantation is another treatment option.
Currently, the most direct and effective way to increase AAT levels in plasma and interstitial lung is by intravenous infusion of pooled alpha-1 antitrypsin (pAAT).
The worldwide market for Alpha 1 Antitrypsin Deficiency Treatment is expected to grow at a CAGR of roughly 9.0% over the next five years, will reach 1980 million US$ in 2023, from 1190 million US$ in 2017, according to a new study.
Market Segment by Manufacturers, this report covers
Pfizer
Baxter
AstraZeneca
Grifols
Teva Pharmaceutical Industries
Boehringer Ingelheim
Kamada Ltd
GlaxoSmithKline
CSL Behring
Shire
LFB Biomedicaments
Abeona Therapeutics
Biogen
Applied Genetic Technologies
Baxalta
Arrowhead Research Corporation
ProBioGen
Chiesi Pharmaceuticals
Curaxys
ProMetic Life Sciences
Market Segment by Regions, regional analysis covers
North America (United States, Canada and Mexico)
Europe (Germany, France, UK, Russia and Italy)
Asia-Pacific (China, Japan, Korea, India and Southeast Asia)
South America (Brazil, Argentina, Colombia etc.)
Middle East and Africa (Saudi Arabia, UAE, Egypt, Nigeria and South Africa)
Market Segment by Type, covers
Augmentation Therapy
Bronchodilators
Corticosteroids
Oxygen Therapy
Market Segment by Applications, can be divided into
Hospitals
Specialty Clinics
Pharmacies
There are 15 Chapters to deeply display the global Alpha 1 Antitrypsin Deficiency Treatment market.
Chapter 1, to describe Alpha 1 Antitrypsin Deficiency Treatment Introduction, product scope, market overview, market opportunities, market risk, market driving force;
Chapter 2, to analyze the top manufacturers of Alpha 1 Antitrypsin Deficiency Treatment, with sales, revenue, and price of Alpha 1 Antitrypsin Deficiency Treatment, in 2016 and 2017;
Chapter 3, to display the competitive situation among the top manufacturers, with sales, revenue and market share in 2016 and 2017;
Chapter 4, to show the global market by regions, with sales, revenue and market share of Alpha 1 Antitrypsin Deficiency Treatment, for each region, from 2013 to 2018;
Chapter 5, 6, 7, 8 and 9, to analyze the market by countries, by type, by application and by manufacturers, with sales, revenue and market share by key countries in these regions;
Chapter 10 and 11, to show the market by type and application, with sales market share and growth rate by type, application, from 2013 to 2018;
Chapter 12, Alpha 1 Antitrypsin Deficiency Treatment market forecast, by regions, type and application, with sales and revenue, from 2018 to 2023;
Chapter 13, 14 and 15, to describe Alpha 1 Antitrypsin Deficiency Treatment sales channel, distributors, traders, dealers, Research Findings and Conclusion, appendix and data source
Frequently Asked Questions
This market study covers the global and regional market with an in-depth analysis of the overall growth prospects in the market. Furthermore, it sheds light on the comprehensive competitive landscape of the global market. The report further offers a dashboard overview of leading companies encompassing their successful marketing strategies, market contribution, recent developments in both historic and present contexts.
- By product type
- By End User/Applications
- By Technology
- By Region
The report provides a detailed evaluation of the market by highlighting information on different aspects which include drivers, restraints, opportunities, and threats. This information can help stakeholders to make appropriate decisions before investing.
Please Select a Format
